Yinxin Wu Selected Research

Yinxin Wu Research Topics

Disease

12	Neoplasms (Cancer) 03/2024 - 01/2022
7	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2022
5	Stomach Neoplasms (Stomach Cancer) 01/2023 - 01/2022
4	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 01/2022
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 01/2022
4	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 01/2022
3	Esophageal Squamous Cell Carcinoma 01/2023 - 01/2022
3	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 01/2022
3	Adenocarcinoma of Lung 01/2023 - 01/2022
3	Osteosarcoma (Osteogenic Sarcoma) 01/2023 - 01/2022
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2022
2	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2022
2	Squamous Cell Carcinoma of Head and Neck 01/2023 - 01/2022
2	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2022
2	Papillary Thyroid Cancer 01/2023 - 01/2022
2	Esophageal Neoplasms (Esophageal Cancer) 01/2023 - 01/2022
2	Glioma (Gliomas) 01/2023 - 01/2022
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2022
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2022
1	Triple Negative Breast Neoplasms 01/2023
1	Nasopharyngeal Carcinoma 01/2023
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2023
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 01/2023
1	Uveal melanoma 01/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022
1	Giant Cell Tumors (Giant Cell Tumor) 01/2022
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022
1	Rheumatoid Arthritis 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Endometrial Neoplasms (Endometrial Cancer) 01/2022
1	Cataract (Cataracts) 01/2022
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2022
1	Osteoarthritis 01/2022
1	Carcinogenesis 01/2022
1	Myotonic Dystrophy (Dystrophia Myotonica) 01/2022
1	Liver Neoplasms (Liver Cancer) 01/2022
1	Laryngeal Neoplasms (Laryngeal Cancer) 01/2022
1	Hemangioma (Angioma) 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2022

Drug/Important Bio-Agent (IBA)

8	Long Noncoding RNAIBA 03/2024 - 01/2022
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2022
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2022
2	Untranslated RNA (Noncoding RNA)IBA 01/2023 - 01/2023
2	Environmental BiomarkersIBA 01/2023 - 01/2023
2	Indicators and Reagents (Reagents)IBA 01/2023 - 01/2023
1	Competitive Endogenous RNAIBA 01/2023
1	ChromatinIBA 01/2023
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2023
1	Tumor Biomarkers (Tumor Markers)IBA 01/2023
1	Oncogene Proteins (Oncogene Protein)IBA 01/2023
1	MicroRNAs (MicroRNA)IBA 01/2023
1	Eph Family Receptors (Eph Receptors)IBA 01/2023
1	EphA1 Receptor (Eph Receptor)IBA 01/2023
1	Ephrin-A1 (Ephrin A1)IBA 01/2023
1	IntegrinsIBA 01/2022

Therapy/Procedure

7	Therapeutics 03/2024 - 01/2022
1	Radiotherapy 03/2024